The U.S. Food and Drug Administration (FDA) has suspended Novavax's experimental combined COVID-19 and flu vaccine clinical ...

The vaccine maker said the regulator placed the hold because of a report of a “serious adverse event” of motor neuropathy in ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu ...

Related: John Jacobs is working to refocus Novavax for a new era “We are working closely with the FDA to provide the necessary information that will allow them to better understand this ...

Novavax’s phase 3 trial in the US is still ongoing with 30,000 participants, but the company hope data already reported from the UK trial will be enough to convince the FDA to approve.

FDA places a clinical hold on Novavax's COVID-19-influenza vaccine trials due to a serious adverse event in a Phase 2 participant. Novavax's COVID-19 IND and European approval for its updated ...

Shares of Novavax (NASDAQ:NVAX) fell roughly 30% Wednesday morning after the U.S. FDA put a clinical hold on the new drug application of its COVID-19 and influenza combination vaccine and ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and stand-alone flu inoculation, sending shares down sharply. The vaccine ...